Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
2024年1月3日 - 9:00PM
Immunocore to present at the
42nd Annual J.P. Morgan
Healthcare Conference
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
& ROCKVILLE, Md., US, 03 January, 2024) Immunocore Holdings plc
(Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage
biotechnology company pioneering and delivering transformative
immunomodulating medicines to radically improve outcomes for
patients with cancer, infectious diseases and autoimmune diseases,
today announced that management will participate in a presentation
at the 42nd Annual J.P. Morgan Healthcare Conference in San
Francisco, California.
The presentation is scheduled for Wednesday,
January 10, 2024, at 9:00 a.m. Pacific Standard Time (PST).
The presentation will be webcast live and can be
accessed by visiting ‘Events’, under ‘News & Events’, via the
‘Investors’ section of Immunocore’s website at www.immunocore.com.
Following the event, a replay of the presentation will be made
available for a limited time.
About ImmunocoreImmunocore is a
commercial-stage biotechnology company pioneering the development
of a novel class of TCR bispecific immunotherapies called ImmTAX –
Immune mobilizing monoclonal TCRs Against X disease – designed to
treat a broad range of diseases, including cancer, autoimmune, and
infectious disease. Leveraging its proprietary, flexible,
off-the-shelf ImmTAX platform, Immunocore is developing a deep
pipeline in multiple therapeutic areas, including five clinical
stage programs in oncology and infectious disease, advanced
pre-clinical programs in autoimmune disease and multiple earlier
pre-clinical programs. The Company’s most advanced oncology TCR
therapeutic, KIMMTRAK has been approved for the treatment of
HLA-A*02:01-positive adult patients with unresectable or metastatic
uveal melanoma in the United States, European Union, Canada,
Australia, and the United Kingdom.
CONTACT: Immunocore
Sébastien Desprez, Head of CommunicationsT: +44 (0) 7458030732E:
sebastien.desprez@immunocore.comFollow on Twitter: @Immunocore
Investor Relations Clayton Robertson,
Head of Investor RelationsT: +1 215-384-4781E:
ir@immunocore.com
Immunocore (NASDAQ:IMCR)
過去 株価チャート
から 5 2024 まで 6 2024
Immunocore (NASDAQ:IMCR)
過去 株価チャート
から 6 2023 まで 6 2024
